The Last Mile of Medicine: Bridging Medical Science and Shareholder Value
Report from 7 July 2026. FDA approval does not guarantee returns for shareholders. We looked at the gap between medical success and commercial success.
Research lead: Denys Zavertany
This report on healthcare stocks was first published on 7 July 2026. Prices, figures and our view are as they stood that day. How the view has played out since is tracked on our Track Record page.
The last mile of medicine is the gap between FDA approval and real returns for shareholders. GeneDx shares fell 49% despite 34% volume growth, while UroGen faced a hard commercial fight even after securing a permanent reimbursement code. The report explains why clinical success protects patients but can still trap investors.
Already have an account? Log in
Continue with a free trial
Get full access to our independent research for 7 days.
Start free trialOr read the Quick Explanation. It is free
Related · same theme
Dismantling the Fed Put: The Warsh Regime and the Capital Preservation Playbook
11 Jul · How This Industry Works
The 90 Basis Point Bet: Auditing Molina’s Path to $25 EPS by 2029
1 Jun · How This Industry Works
The Nitrogen Lag: Capital Cycles and the Arbitrage of Market Fear
27 May · How This Industry Works
Educational content only. Not investment advice.